A potential immunotherapy approach: Mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model

Vaccine

Volumn 25, Issue 47, 2007, Pages 8091-8099

  Ma, Yanbing ^a,b   Ma, Allan G ^a   Peng, Zhikang ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MANITOBA INSTITUTE OF CHILD HEALTH   (Canada)

Author keywords

IL 13; Mucosal immunization; Vaccine

Indexed keywords

AUTOANTIBODY; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 13; OVALBUMIN; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG EFFICACY; EOSINOPHIL; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; TH2 CELL; VACCINATION; VIRUS LIKE AGENT;

ANIMALS; ASTHMA; AUTOANTIGENS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; EOSINOPHILS; FEMALE; HEPATITIS B CORE ANTIGENS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN-13; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; RECOMBINANT PROTEINS; RIBONUCLEOPROTEINS; VACCINATION; VIRION;

EID: 35448939297     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.009     Document Type: Article

References (33)

1. Wills-karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 202 (2004) 175-190
2. Kumar R.K., Herbert C., Webb D.C., Li L., and Foster P.S. Effects of anticytokine therapy in a mouse model of chronic asthma. Am J Respir Crit Care Med 170 10 (2004) 1043-1048
3. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., et al. Interleukin-13: central mediator of allergic asthma. Science 282 5397 (1998) 2258-2261
4. Holgate S.T., Chuchalin A.G., Hebert J., Lotvall J., Persson G.B., Chung K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34 4 (2004) 632-638
5. Sandborn W.J. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 5 1 (2005) 10-18
6. Zagury D., Le Buanec H., Bizzini B., Burny A., Lewis G., and Gallo R.C. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 14 2 (2003) 123-137
7. Arendse B., Van Snick J., and Brombacher F. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 174 4 (2005) 2205-2211
8. Bertin-Maghit S.M., Capini C.J., Bessis N., Chomilier J., Muller S., Abbas A., et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 23 33 (2005) 4228-4235
9. Rohn T.A., Jennings G.T., Hernandez M., Grest P., Beck M., Zou Y., et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 36 11 (2006) 2857-2867
10. Ma Y., Hayglass K.T., Becker A.B., Fan Y., Yang X., Basu S., et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 176 5 (2007) 439-445
11. Pumpens P., and Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44 2-3 (2001) 98-114
12. Lobaina Y., Garcia D., Abreu N., Muzio V., and Aguilar J.C. Mucosal immunogenicity of the hepatitis B core antigen. Biochem Biophys Res Commun 300 3 (2003) 745-750
13. Lobaina Y., Palenzuela D., Pichardo D., Muzio V., Guillen G., and Aguilar J.C. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 42 3 (2005) 289-294
14. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 10 (1999) 1157-1163
15. Francis M.J., Hastings G.Z., Brown A.L., Grace K.G., Rowlands D.J., Brown F., et al. Immunological properties of hepatitis B core antigen fusion proteins. Proc Natl Acad Sci USA 87 7 (1990) 2545-2549
16. Yang G., Li L., Volk A., Emmell E., Petley T., Giles-Komar J., et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther 313 1 (2005) 8-15
17. Zhu Z., Ma B., Zheng T., Homer R.J., Lee C.G., Charo I.F., et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 168 6 (2002) 2953-2962
18. Ma B., Liu W., Homer R.J., Lee P.J., Coyle A.J., Lora J.M., et al. Role of CCR5 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 176 8 (2006) 4968-4978
19. Bochner B.S., Klunk D.A., Sterbinsky S.A., Coffman R.L., and Schleimer R.P. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 154 2 (1995) 799-803
20. Kuperman D.A., Huang X., Koth L.L., Chang G.H., Dolganov G.M., Zhu Z., et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 8 8 (2002) 885-889
21. Shore S.A. Direct effects of Th2 cytokines on airway smooth muscle. Curr Opin Pharmacol 4 3 (2004) 235-240
22. Lanone S., Zheng T., Zhu Z., Liu W., Lee C.G., Ma B., et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest 110 4 (2002) 463-474
23. Kibe A., Inoue H., Fukuyama S., Machida K., Matsumoto K., Koto H., et al. Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways. Am J Respir Crit Care Med 167 1 (2003) 50-56
24. Vanlandschoot P., Cao T., and Leroux-Roels G. The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure. Antiviral Res 60 2 (2003) 67-74
25. Ulrich R., Nassal M., Meisel H., and Kruger D.H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 50 (1998) 141-182
26. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20 25-26 (2002) 3104-3112
27. Milich D.R., Chen M., Schodel F., Peterson D.L., Jones J.E., and Hughes J.L. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci USA 94 26 (1997) 14648-14653
28. Lazdina U., Cao T., Steinbergs J., Alheim M., Pumpens P., Peterson D.L., et al. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells. J Virol 75 14 (2001) 6367-6374
29. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., and Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol 168 10 (2002) 4951-4959
30. Chackerian B., Lenz P., Lowy D.R., and Schiller J.T. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169 11 (2002) 6120-6126
31. Epstein M.M. Do mouse models of allergic asthma mimic clinical disease?. Int Arch Allergy Immunol 133 1 (2004) 84-100
32. Humbles A.A., Lloyd C.M., McMillan S.J., Friend D.S., Xanthou G., McKenna E.E., et al. A critical role for eosinophils in allergic airways remodeling. Science 305 5691 (2004) 1776-1779
33. Lee J.J., Dimina D., Macias M.P., Ochkur S.I., McGarry M.P., O'Neill K.R., et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305 5691 (2004) 1773-1776